A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

CompletadoFase 3ClinicalTrials.gov

ID: NCT05665595Tipo: INTERVENTIONALInicio: 19 de ene de 2023Fin estimado: 26 de sept de 2025

Traducción no disponible, mostrando original

Resumen

The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.

Descripción detallada

With Amendment 4, participants will discontinue treatment with pembrolizumab/vibostolimab. The protocol-specified futility analysis of the primary outcome measure was completed with a data cut-off of 06-Mar-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure. Per protocol, 192 participants enrolled after the primary completion date and will be analyzed in the End of Trial analysis.

Elegibilidad

Edad mínima: 12 YearsSexo: ALL

Criterios de inclusión

Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines
Has not received any prior systemic therapy for melanoma beyond surgical resection
Has had no more than 12 weeks between final surgical resection and randomization
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Criterios de exclusión

Has ocular, mucosal, or conjunctival melanoma
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
Has not adequately recovered from major surgical procedure or has ongoing surgical complications
Has received prior radiotherapy within 2 weeks of start of study intervention or has had a history of radiation pneumonitis
Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration
Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has an active infection requiring systemic therapy
Has had an allogenic tissue/solid organ transplant

Intervenciones

biological

Pembrolizumab/Vibostolimab

Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations

biological

Pembrolizumab

Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations

Ubicaciones

Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Instituto Alexander Fleming-Alexander Fleming ( Site 0209)

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)

Buenos Aires, Buenos Aires F.D., Argentina

Instituto de Oncología de Rosario ( Site 0206)

Rosario, Santa Fe Province, Argentina

Sanatorio Finochietto ( Site 0212)

Buenos Aires, Argentina

Clinica Adventista Belgrano-Oncology ( Site 0211)

CABA, Argentina

Patrocinadores

PrincipalMerck Sharp & Dohme LLC

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3, Randomized, Double-blind, Active-Comparator-Co... | EligiMed